Your browser doesn't support javascript.
loading
Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma.
Schneider, Meike; Schüler, Julia; Höfflin, Rouven; Korzeniewski, Nina; Grüllich, Carsten; Roth, Wilfried; Teber, Dogu; Hadaschik, Boris; Pahernik, Sascha; Hohenfellner, Markus; Duensing, Stefan.
Affiliation
  • Schneider M; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Schüler J; Oncotest GmbH, Freiburg, Germany.
  • Höfflin R; Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Korzeniewski N; Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Grüllich C; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Roth W; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany; Department of Pathology, University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Teber D; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Hadaschik B; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Pahernik S; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Hohenfellner M; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of Medicine, Heidelberg, Germany.
  • Duensing S; Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Molecular Urooncology, Department of Urology, University of Heidelberg School of Medicine, Heidelberg, Germany; Center for Kidney Tumors, National Center for Tumor Disease and University of Heidelberg School of
Urol Oncol ; 32(6): 877-84, 2014 Aug.
Article in En | MEDLINE | ID: mdl-24929890
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Predisposition to Disease / Precision Medicine / Molecular Targeted Therapy / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2014 Document type: Article Affiliation country: Germany Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Predisposition to Disease / Precision Medicine / Molecular Targeted Therapy / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies / Screening_studies Limits: Humans Language: En Journal: Urol Oncol Journal subject: NEOPLASIAS / UROLOGIA Year: 2014 Document type: Article Affiliation country: Germany Country of publication: United States